282P - Clinico-Pathological Characteristics and Outcome in Recurrent Renal Cell Carcinoma

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Renal Cell Cancer
Presenter Priya Tiwari
Authors P. Tiwari1, L. Kumar1, G. Singh2, S. Thulkar3, A. Seth4
  • 1Medical Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 2Pathology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 3Radiodiagnosis, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 4Urology, All India Institute of Medical Sciences, 110029 - New Delhi/IN



Recurrences in renal cell cancer (RCC) affects approximately one-third of patients after curative nephrectomy. However, studies from Indian subcontinent are scarce. We retrospectively analysed data of patients suffering from RCC over last one decade to find relapse rate and pattern in Indian cohort from our centre.


All patients with RCC who underwent nephrectomy from 2004 to 2013 at our centre were included. Recurrence free survival (RFS) was calculated from date of surgery to date of recurrence or death. Cox Regression Model (Univariate and multivariate) was applied to identify significant prognostic factors.


Overall 292 patients were included in the analysis. Median age was 50 years (range-19 to 84 years). Male: female ratio was 3:1. Radical and partial nephrectomy were performed in 275(94.2%) and 14(4.8%) patients respectively. Clear cell was most common histological subtype (72%). T1, T2, T3 and T4 stage were detected in 89(30.7%), 86(29.8%), 105(36.2%) and 12(4.2%) patients respectively. One hundred and thirty six patients (46.6%) had recurrence. Eighty six patients (61.8%) relapsed at distant sites, 14(8.82%) patients relapsed at loco-regional site whereas 36 (25%) had both distant and loco-regional recurrence. Median time to develop recurrance was 18 months. Approximately 19 % patient had disease reappearance after five year. Factors predicting Shorter RFS in multivariate analysis were weight loss (P=0.004), Fuhrman grade 3 or 4 (P<0.0001), Presence of necrosis (P<0.0001) and higher tumor stage (P=0.005).


Compared to previous studies, our patients had higher rates of recurrence in general and loco-regional recurrence in particular. However, predictive factors remain similar.

Clinical trial indentification

Not applicable